Ferran Prat, Vice President of Strategic Industry Ventures MD Anderson Cancer Center (Board Observer)
Ferran joined MD Anderson in 2013, and leads the development of alliances and partnerships with pharmaceutical, biotech, diagnostics, imaging, laboratory medicine and other industry partners. Prior to joining MD Anderson he worked at Alere Inc., a firm dedicated to developing health management services and solutions, including diagnostic tools and tests. At Alere, Ferran led a business turnaround and integrated three businesses in São Paulo and Belo Horizonte, Brazil. He also served as the head of both the Oncology and the Women’s Health Divisions in San Diego, where he was responsible for all pre-commercialization activities, launch and post-launch product management.
Prior to Alere, Ferran held a number of industry and academic positions, including vice president for licensing at Biosite Inc., management consultant at McKinsey & Co., engineer at Chromogenia-Units and researcher at the University of California – Los Angeles. In these roles, he in-licensed and out-licensed new technologies, led and executed strategic plans, coordinated intellectual property agreements among private and public sector entities, and conducted basic science research that led to multiple peer-reviewed articles.
Ferran has a Ph.D. in organic chemistry from the University of California – Los Angeles and a J.D. from the University of San Diego School of Law.
Giulio Draetta, M.D., Ph.D. is currently Vice-President and Head of the Therapeutics Discovery Division at MD Anderson Cancer Center and Professor of Molecular and Cellular Oncology (Board Observer)
Giulio Draetta, M.D., Ph.D. is currently Vice-President and Head of the Therapeutics Discovery Division at MD Anderson Cancer Center and Professor of Molecular and Cellular Oncology. Prior to joining MD Anderson, he was chief research business development officer and deputy director of the Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute. Dr. Draetta has also served as head of oncology drug discovery at Pharmacia and Merck, where he focused on the discovery and development of inhibitors of receptor tyrosine kinase signaling, cell division cycle inhibitors, novel cytotoxics, developmental pathway inhibitors, and epigenetics drugs. He was co-founder and vice president of research for Mitotix and co-founded Karyopharm, Inc. During his time in academia, he served as an investigator at the Cold Spring Harbor Laboratory, the European Molecular Biology Laboratory in Heidelberg, Germany and at the European Institute of Oncology. He spearheaded fundamental research in the biology of the eukaryotic cell division cycle and of DNA damage induced checkpoints. Dr. Draetta received his medical and post-graduate degrees from the University of Naples Medical School, Italy.
William Slattery, Partner at Deerfield Management Company
Bill Slattery is a Partner on the Private Transactions team at Deerfield, which he joined in 2000. He began his professional career studying immune system complications associated with End Stage Renal Disease. Prior to joining Deerfield, Bill was a senior healthcare analyst between 1990 and 2000 at Amerindo Investment Advisors overseeing biotechnology investments. He has held various positions in research including those at National Medical Enterprises, Johnson & Johnson, and HMSS. Bill has a degree in Biology from State University of New York at Albany and completed coursework in Immunology at the Graduate School-New Brunswick, Rutgers University.
Robert Jackson, M.D., Partner and Chief Science Officer for Deerfield Management Company
As a Partner on the Biotech team at Deerfield since 2001 and the Chief Science Officer since 2014, Bob Jackson provides extensive research and analysis on individual companies operating in the healthcare industry. Prior to joining Deerfield, Bob was a healthcare analyst at Janus Capital from 1999 to 2001. Previously, he founded and managed a group ophthalmology practice. Bob earned his undergraduate degree at Rollins College and his medical degree at West Virginia University. He earned an M.B.A. with distinction from the Wharton School at the University of Pennsylvania, was a Cleveland Fellow from Case Western Reserve University, spent a year at the Royal Melbourne Hospital in Australia, completed his ophthalmology residency at Case Western Reserve University and was Chief Resident in his final year. Dr. Jackson is also a CFA charterholder.
Roger Griesmeyer, Partner, Andrews Kurth Kenyon LLP
Roger is a Partner at Andrews Kurth Kenyon LLP, a global law firm with a significant presence in the life sciences sector. Roger advises a variety of clients, including private equity and venture capital funds, companies and other interested parties on their acquisition, investment and disposition strategies. Roger specializes in sophisticated, cross-border transactions across a number of industries, including healthcare/pharma, manufacturing, luxury consumer products, film and television, real estate and technology. He also guides boards of directors, special committees and investors on growth strategy, special situations, restructurings and other corporate governance issues. Roger is an adjunct corporate drafting professor at Brooklyn Law School and serves on the Alumni Board. He is also a member of the ’98 Executive Committee for Dartmouth College.